MBIOHIGH SIGNALFINANCIAL10-K

MBIO removed substantial doubt language regarding going concern while showing dramatically improved financial performance and balance sheet strength.

The removal of going concern warnings combined with substantially reduced losses suggests the company has successfully navigated its previous liquidity crisis. However, new risk factors around future funding needs and Nasdaq compliance issues indicate ongoing operational challenges that investors should monitor closely.

Comparing 2026-03-19 vs 2025-03-28View on EDGAR →
FINANCIAL ANALYSIS

MBIO's financial position improved markedly, with total assets nearly doubling to $17.6M while total liabilities declined substantially to $8.1M. The company's net losses were meaningfully reduced and operating cash flow consumption decreased notably, signaling improved operational efficiency. This dramatic balance sheet strengthening aligns with the removal of going concern language and suggests successful execution of the company's strategic pivot.

FINANCIAL STATEMENT CHANGES
Total Assets
Balance Sheet
+89%
$9.3M$17.6M

Asset base grew 89% — expansion through organic growth, acquisitions, or capital deployment.

Net Income
P&L
+87.8%
-$15.8M-$1.9M

Net income grew 87.8% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+85%
-$16.2M-$2.4M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Operating Cash Flow
Cash Flow
+53.9%
-$11.4M-$5.3M

Operating cash flow surged 53.9% — exceptional cash generation, highest quality earnings signal.

Total Liabilities
Balance Sheet
-38.8%
$13.2M$8.1M

Liabilities reduced 38.8% — deleveraging improves balance sheet strength and financial flexibility.

Current Liabilities
Balance Sheet
-37.2%
$12.6M$7.9M

Current liabilities reduced — improved short-term financial position and working capital health.

LANGUAGE CHANGES
NEW — 2026-03-19
PRIOR — 2025-03-28
ADDED
We may in the future need to raise additional funding, which may not be available on acceptable terms to us, or at all.
Risks Inherent in Drug Development and Commercialization Preclinical and clinical development are both highly speculative and carry a high failure risk.
Our competitors may develop treatments for our product candidates target indications, which could limit our product candidates commercial opportunity and profitability, if approved.
We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.
We have previously failed to satisfy certain continued listing rules of The Nasdaq Stock Market LLC ( Nasdaq ), and if we again are unable to meet the continued listing requirements and/or regain compliance with such rules, our Common Stock may be subject to delisting from The Nasdaq Capital Market.
+7 more — sign up free →
REMOVED
There is substantial doubt regarding our ability to continue as a going concern.
We will need to raise additional financing in upcoming periods, which may not be available on acceptable terms to us, or at all.
Our strategic pivot and focus on our lead product candidates, MB-109 and MB-106, and our disposal of non-core assets, including our facility, may not result in the cost savings we anticipate and could result in total costs and expenses that are greater than expected.
Risks Inherent in Drug Development and Commercialization Preclinical development is highly speculative and carries a high failure risk.
Our competitors may develop treatments for our products target indications, which could limit our product candidates commercial opportunity and profitability.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →